SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
Trial Parameters
Brief Summary
To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria: 1. Patients voluntarily participate in this study, sign informed consent, and demonstrate good compliance. 2. Patients with histologically or pathologically confirmed EGFR wild-type and EGFR mutant non-small cell lung cancer resistant to treatment. 3. The number of brain metastases is ≤ 5, and the patient has at least one assessable brain metastasis on imaging (RECIST 1.1). Additionally, the patient's physical condition allows for the completion of stereotactic radiosurgery. 4. Age between 18-80 years, gender unspecified. 5. ECOG performance status of 0 or 1; expected survival of no less than 3 months. 6. Regardless of prior treatment, it is only required that concurrent oral administration of anlotinib during radiotherapy without intervention regarding subsequent treatment regimens. 7. Oral administration of anlotinib including, but not limited to, third-line therapy. 8. Good function of major organs, with laboratory test indicators meeting the following criteria: